Todos Medical Announces Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. for Tollovid(R) Products Covering 30 Countries in Europe
- The agreement calls for a minimum of 500,000 bottles in sales over 18 months
- T-Cell Protect to invest 1 million euros in Todos to support development of Tollovir, the Company's 3CL Protease Inhibiting Antiviral Drug Candidate
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.